Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome (Bevacizumab)
The Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Prospective interventional clinical trial
Single center, outcome assessor-masked, active control, randomized controlled trial
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Songkhla
-
Hat-yai, Songkhla, Thailand, 90110
- Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary open angle glaucoma with primary mmc-trabeculectomy indication
Exclusion Criteria:
- combined phacoemulsification with trabeculectomy
- no more than 6 month of cataract surgery before trabeculectomy
- revised trabeculectomy
- active uveitic glaucoma
- neovascular glaucoma
- par planar vitrectomy
- conjunctival surgery
- allergy to bevacizumab or mitomycin C
- ischemic heart disease
- cerebrovascular disease
- renal failure
- liver failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Mitomycin c
Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
|
Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Other Names:
|
|
Experimental: Bevacizumab
Bevacizumab injection of 1.25m/0.05
cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
|
Bevacizumab injection of 1.25m/0.05
cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraocular pressure
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Bleb characteristic grading
Time Frame: 6 month
|
6 month
|
|
systemic Blood pressure
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Glaucoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibiotics, Antineoplastic
- Bevacizumab
- Mitomycins
- Mitomycin
Other Study ID Numbers
Other Study ID Numbers
- EC 53-296-02-1-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.